Grace Kong and Michael Dickinson have both been appointed to the position of Honorary Clinical Associate Professor in the Sir Peter MacCallum Department of Oncology at the University of Melbourne.

Associate Professor Grace Kong is a nuclear medicine physician who commenced at Peter Mac in 2004 as a registrar, and then returned as a consultant after completing a PET and radionuclide therapy fellowship at the Royal Marsden Hospital, UK.

She is the Radionuclide Therapy Modality Lead for Cancer Imaging and chair of the weekly Neuroendocrine Tumour Multidisciplinary Meeting at Peter Mac.

Grace has a special interest in theranostic applications using radionuclide therapy for the management of neuroendocrine tumours (NET).

She has contributed significantly to clinical research activities, resulting in multiple practice-changing NET imaging and therapy outcome data publications from Peter Mac and two international clinical guidelines. 

Grace continues her cutting-edge research as the principal investigator of several trials supported by a 2019 Foundation Discovery Partner Fellowship and as co-investigator of the US$1.5 million NET Research Foundation research grant.

She is a passionate patient advocate raising awareness of NET, speaking at patient symposiums and being a vocal advocate for equitable funding of research in rare tumours types.

Associate Professor Michael Dickinson has been the Disease Group Lead for Aggressive Lymphomas at Peter Mac and the Royal Melbourne Hospital since the merger of the departments in 2016. He is also the Deputy Clinical Director and a member of the steering committee for the Centre of Excellence in Cellular Immunotherapy at Peter Mac.

Michael has been the principal investigator of many clinical trials, including the first-in-human trial of the novel bi-specific antibody Glofitamab, which demonstrated major activity in relapsed lymphoma.

He is Chair of the Cancer Trials Australia Haematology Tumour Group and has 64 publications in peer-reviewed journals and two book chapters. Michael has been an invited speaker at many national and international meetings and led the COALITION trial investigating Glofitamab in the first-line treatment of aggressive lymphoma.

He currently supervises a University of Melbourne PhD student and has supervised several haematology/pathology fellows and trainees based at Peter Mac, exemplifying his dedication to nurturing the future generation of emerging haematologists.

Congratulations both!